Intraperitoneal Chemotherapy

In this video, Robert DeBernardo, MD, discusses his research on hyperthermic intraperitoneal chemotherapy among patients with kidney disease, which he presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Adding hyperthermic intraperitoneal chemotherapy to cytoreductive surgery did not significantly prolong PFS or OS among women with advanced epithelial ovarian cancer, according to a single-blind, randomized study in JAMA Surgery.

Upfront cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy may be a viable treatment for certain older women with ovarian cancer, according to results of a study published in Annals of Surgical Oncology.